For example, the inhibition of EZH2—the synthetic lethal partner of ARID1A—caused tumor regression in ARID1A‐mutated ovarian cancer cells38 and associated with hepatocellular carcinoma metastases.39 Here, EZH2 is linked to ovarian carcinoma.